This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

David Best is a liar.

He certainly fooled a lot of people me included.

If the pipeline of products is still good and potentially commercial then this could be a buying opportunity? Would MMG become a takeover target?

Hi Andy, fundamentally the pipeline remains as it has been; with potential and a strong case for big pharma interest should trials prove positive. As you point out we have seen only a fornight ago with CEN that a tumbling share price combined with innovative products could lead to buyout interest. My concern with this co. at the moment is the position with Best and the fact that his personal situation was almost unknown despite the fact that it was a clearly price sensitive issue. He has been at the forefront of investor relations yet things seem to have boken down and the company is experiencing internal issues close to mutiny. Still, pipeline remains intact...as far as we know. Dr Stephenson is still on board...as far as we know and as long as there is enough cash MMI may actually produce the goods; in which case a buyout would obviousy be at a rate far higher than today. Despite the fact that this has always been an extremely speculative share, the price has held up reasonably over the past 18 months on hope alone suggesting that this may well be a buying opp...?

There must be a reason for the boardroom bust up,which does not bode well. Best to steer clear until this becomes known to shareholders.IMHO.

Best stay clear.... pun intended.

This is to be avoided...sp moving downwards by the day.

I was in 2 years ago at 50-80p and took profits when it hit a ridiculous 280p.
Had a dabble agian after cash was raised at 120p and sold at 180p and been on watchlist ever since. There seems to be a large potential and I expect once all is clear with what is going on there will be a chance for both trading and investing profits to be made.

Agree
This has fallen from 150p to 4p in the past and revovered rapidly.
When dust settles and when appetite develops again for Biotech stocks it could happen again.
It may take some time but its definitely one to be watched again very closely.

There are after all 3 potential blockbusters in pipeline and the technology is not where the failure has been.

Well should it fall back to 3p I'm in again caesar but not before.

20p now...3p coming soon, mitzy

Its a shame hlyeo but 3p is about the size of it.

I think 3p is a bit pessimistic!!! they still have the 3 products, and despite the management f~cking up the business side of the company (and there is no doubt about that), the 3 treatments do still appear to be progressing, albeit slower than the deposed Best would have had us believe.
This might come good some day.....
For the record, I still hold a load of MMG shares. I know now this is blind stupidity rather than anything else!!

just a shame that best was the bullsh***er supreme
wether there is anything there of value must be open to doubt
rights issue coming? I would think that 10p might be a good price to raise at.

Management is always the ones that f#@k up companies, especially WNG, SEO and EME.

Your right notlob I admit DB took me for a fool and I fell for it the company is worthless thanks to him I should have known better than believe a bullshitter.

sorry to hear that, mitzy
guess he fooled lots of folks
didn't realise till recently that Best + his wife were oulling out a ftse100 salary between them (500K+)
Also, i think Best's wife was down as IT director, I mean, how much IT can there be in a company the size of MMI, certainly not the 200K or so she was pulling out the company.
I remember meeting Best quite a few years ago at an exhibition, he told be Cellfactors, at that time MMI owned a big chunk of them, would be ftse 100 in a few years, sadly they went bust and I lost a few bob on that one.

I met them a fw times and they were very convincing he said MMI was a 500 mill company in the making and now its worthless.

I got out of MMG at 110p. You can say David Best is a conman.

NeilMccloyd: - May I?
The "3-treatments" are (in reality) three Streams , = dreams - each becomming several "products", Each "product" requires a huge investment to get through trials/pass regulation/into sales.
- - - Oh, and finally they need a sales Partner. More pressing, they need CASH as well as a Parner to bankroll the PhaseIII trials in a few years time. Trials are notoriously expensive (something like $20m, but it could be pounds, the number is so big). Plus "time" - I recall Oxford Bio took 10-years and not one product is through!(Although OXB has not had any serious setbacks)
MMI is certainly "interesting" - but that is all - yes I agree the Salary looks very steep, esp. in view of their cash position (= under 10m, probably as low as 1m)

So where does that leave the value to shareholders, who are unlikely to want ( or be able), to cough up 20m for each product -
Dunno - for whichever product they go with, there are risks and the one product you can't make is "time" - that's what they ran out of - had they had more time (before the bubble burst) they would still be here, telling everyone it's worth 's.
Well, it ain't - the issue (now), is what is anyone prepared to invest? Would shareholders cough up 50p/share (to raise 20m-ish).....anyone that holds say 5k-worth at 1 =5000 will have lost 4k(today), yet need to find about 2500 -
Could investors be willing......? Maybe under certain conditions, like the Management is Bio-background and is rewarded as the Trials go forward, with the enphasis on keeping cash-spend low. The past-management is no longer an issue - they have no place IMHO, moving the company into the Medico Trials Arena.

Were there tell-tale signs?
1) The company name was a bit OTT, considering they didn't sell anything.
2) They didn't invent the products - they have some arrangement with a University, which is far from made clear
3) In nearly 8-years no phase trials had been concluded, nor a partner found for products that were (told to punters), world-class life-enhancing curatives.
(DYOR - anyone disagree?)

Anyone here, willing to invest ots to resolve [MMG] funding?
I wonder.
(or-= alternative views!)